TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2015 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Roth Affirms TG Therapeutics (TGTX) at 'Focus Pick'; Sees Strong Results in 2016
March 8, 2016 11:41 AM ESTRoth Capital reaffirms TG Therapeutics (Nasdaq: TGTX) with a Buy (and Focus Pick) rating and $33 price target following the company's FY15 results report, which was made late Monday.
Joseph Pantginis, Ph.D., commented, The GENUINE Phase III (under SPA) is now enrolling at >150 U.S. sites and complete enrollment is expected by year-end and top-line data in early 2017. TG... More
TG Therapeutics (TGTX) Reports Q4 Loss of $0.37/Share
March 7, 2016 4:03 PM ESTTG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.37), versus ($0.48) reported last year. Revenue for the quarter came in at $38.1 million, versus $38.1 million reported last year.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
... More